<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919643</url>
  </required_header>
  <id_info>
    <org_study_id>BAFF</org_study_id>
    <nct_id>NCT03919643</nct_id>
  </id_info>
  <brief_title>BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE</brief_title>
  <acronym>BAFF</acronym>
  <official_title>B Cell Activating Factor Belonging to the TNF (Tumor Necrosis Factor) Family (BAFF) and a Proliferation-inducing Ligand (APRIL) in Patients With Systemic Lupus Erythematosus: Investigating Biomarkers for the Response to the Belimumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is intended to identify the routes on which BAFF and APRIL act in order to
      detect possible future candidates to Belimumab treatment among patients diagnosed of SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN Establish the influence of certain polymorphisms in the levels of expression of
      different transcripts and proteins.

      Quantify the levels of B cell activating factor belonging to the TNF family (BAFF) and a
      proliferation-inducing ligand (APRIL) in serum and urine of patients and controls by
      Enzyme-Linked Immunosorbent Assay (ELISA). BAFF Determine the expression levels of different
      BAFF and APRIL transcripts in peripheral blood mononuclear cells from patients and controls
      using a digital PCR (polymerase chain reaction) system.

      Compare distribution of gene polymorphisms in BAFF and APRIL in patients and controls. by
      sequencing the exome of the ligand and receptor genes using next generation sequencing (NGS).

      Correlate the transcript and protein levels with clinical manifestations and disease
      activity.

      The results of the quantification of anti- double-stranded deoxyribonucleic acid.(dsDNA)
      antibody levels tests will be recorded together with those demographics,
      clinical-epidemiological and response to the treatment.data.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improve knowledge of B Cell activating factor belonging to the TNF (Tumor necrosis factor) family (BAAF) system in order to identify those SLE (Systemic Lupus Erythematous) patients that are candidate for treatment with anti-BAFF.</measure>
    <time_frame>from data of Informed consent form signature to finish of follow-up (1 Year)</time_frame>
    <description>Quantify physiological parameters (levels of BAFF and APRIL) in serum and urine of patients and controls by ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the influence of certain polymorphisms in the levels of expression of different transcripts and proteins.</measure>
    <time_frame>from data of Informed consent form signature to finish of follow-up (1 Year)</time_frame>
    <description>Determine the expression levels of different physiological parameters (BAFF and APRIL transcripts) in peripheral blood mononuclear cells from patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate the transcript and protein levels with clinical manifestations and disease activity.</measure>
    <time_frame>from data of Informed consent form signature to finish of follow-up (1 Year)</time_frame>
    <description>Quantify anti-dsDNA levels recording clinical symptoms and SLE-DAI (Systemic Lupus Erythematosus Disease Activity Index)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>BAFF Polymorphism</condition>
  <arm_group>
    <arm_group_label>SLE patients with nephritis</arm_group_label>
    <description>No intervention. Peripheral blood and urine samples will be obtained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLE patients with without nephritis</arm_group_label>
    <description>No intervention. Peripheral blood and urine samples will be obtained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls (blood donors)</arm_group_label>
    <description>No intervention. Peripheral blood and urine samples will be obtained</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        SLE (Sistemic Lupus Disease) with and without nephritis and healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Women18-60 years old

          -  For patients only treated with conventional drugs (without immunosuppressive or
             biological treatment )

          -  For Healthy controls: no autoimmune diseases (blood donors) diagnoses
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisca González- Escribano, PhD</last_name>
    <phone>0034955012144</phone>
    <email>mariaf.gonzalez.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara Rosso-Fernández, MD-PhD</last_name>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing the data collected and analysed with the scientific community by publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>When study is finished</ipd_time_frame>
    <ipd_access_criteria>Data publication for collaborator, data base registration of results if applicable.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

